131 related articles for article (PubMed ID: 30602061)
21. Somatic mutations of the mitochondrial genome in Chinese patients with Ewing sarcoma.
Yu M; Wan Y; Zou Q
Hum Pathol; 2013 Jul; 44(7):1350-6. PubMed ID: 23375644
[TBL] [Abstract][Full Text] [Related]
22. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
23. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM
Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911
[TBL] [Abstract][Full Text] [Related]
24. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
[TBL] [Abstract][Full Text] [Related]
25. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
26. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C; Ordóñez JL; García-Domínguez DJ; Sevillano V; Llombart-Bosch A; Szuhai K; Scotlandi K; Alberghini M; Sciot R; Sinnaeve F; Hogendoorn PC; Picci P; Knuutila S; Dirksen U; Debiec-Rychter M; Schaefer KL; de Álava E
Oncogene; 2012 Mar; 31(10):1287-98. PubMed ID: 21822310
[TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.
Cash T; McIlvaine E; Krailo MD; Lessnick SL; Lawlor ER; Laack N; Sorger J; Marina N; Grier HE; Granowetter L; Womer RB; DuBois SG
Pediatr Blood Cancer; 2016 Oct; 63(10):1771-9. PubMed ID: 27297500
[TBL] [Abstract][Full Text] [Related]
28. CCT6A, a novel prognostic biomarker for Ewing sarcoma.
Jiang J; Liu C; Xu G; Liang T; Yu C; Liao S; Zhang Z; Lu Z; Wang Z; Chen J; Chen T; Li H; Zhan X
Medicine (Baltimore); 2021 Jan; 100(4):e24484. PubMed ID: 33530265
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma.
Yu Y; Shang R; Chen Y; Li J; Liang Z; Hu J; Liu K; Chen C
Biomed Pharmacother; 2018 Apr; 100():108-115. PubMed ID: 29425745
[TBL] [Abstract][Full Text] [Related]
30. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis.
Machado I; Yoshida A; Morales MGN; Abrahão-Machado LF; Navarro S; Cruz J; Lavernia J; Parafioriti A; Picci P; Llombart-Bosch A
Ann Diagn Pathol; 2018 Jun; 34():1-12. PubMed ID: 29661713
[TBL] [Abstract][Full Text] [Related]
31. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
32. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
Wagner MJ; Gopalakrishnan V; Ravi V; Livingston JA; Conley AP; Araujo D; Somaiah N; Zarzour MA; Ratan R; Wang WL; Patel SR; Lazar A; Ludwig JA; Benjamin RS
Oncologist; 2017 Oct; 22(10):1271-1277. PubMed ID: 28710342
[TBL] [Abstract][Full Text] [Related]
33. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.
Zhang N; Liu H; Yue G; Zhang Y; You J; Wang H
PLoS One; 2016; 11(4):e0153546. PubMed ID: 27077911
[TBL] [Abstract][Full Text] [Related]
34. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
35. Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma.
Marrano P; Shago M; Somers GR; Thorner PS
Am J Surg Pathol; 2018 Jun; 42(6):744-749. PubMed ID: 29543677
[TBL] [Abstract][Full Text] [Related]
36. Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management.
Krakorova DA; Kubackova K; Dusek L; Tomas T; Janicek P; Tucek S; Prausova J; Kiss I; Zambo I
Pathol Oncol Res; 2018 Jul; 24(3):623-630. PubMed ID: 28803261
[TBL] [Abstract][Full Text] [Related]
37. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Sand LG; Scotlandi K; Berghuis D; Snaar-Jagalska BE; Picci P; Schmidt T; Szuhai K; Hogendoorn PC
Eur J Cancer; 2015 Nov; 51(17):2624-33. PubMed ID: 26428435
[TBL] [Abstract][Full Text] [Related]
38. Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Société Française des Cancers de L'Enfant.
Cohen-Gogo S; Cellier C; Coindre JM; Mosseri V; Pierron G; Guillemet C; Italiano A; Brugières L; Orbach D; Laurence V; Delattre O; Michon J
Pediatr Blood Cancer; 2014 Dec; 61(12):2191-8. PubMed ID: 25176412
[TBL] [Abstract][Full Text] [Related]
39. Prospective Clinical Genomic Profiling of Ewing Sarcoma:
Ogura K; Elkrief A; Bowman AS; Koche RP; de Stanchina E; Benayed R; Mauguen A; Mattar MS; Khodos I; Meyers PA; Healey JH; Tap WD; Hameed M; Zehir A; Shukla N; Sawyers C; Bose R; Slotkin E; Ladanyi M
JCO Precis Oncol; 2022 Aug; 6():e2200048. PubMed ID: 35952322
[TBL] [Abstract][Full Text] [Related]
40. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
